Menaquinone biosynthesis: a drug target in Gram-positive bacteria View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2001-2008

FUNDING AMOUNT

320260 USD

ABSTRACT

Project Summary: Potent inhibitors of menaquinone synthesis (specifically MenA) in M. tuberculosis have been identified, which are also effective inhibitors of mycobacterial growth. Since utilization of menaquinone is a characteristic of Gram-positive organisms, these compounds are also active against organisms such as methicillin resistant Stapylococcus aureus and Staphylococcus epidermidis, and are expected to be effective against Bacillus anthracis and Listeria monocytogenes as well. The compounds identified as MenA inhibitors here, were first developed as cholesterol synthesis inhibitors and, as such, are known to be bioavailable in mammals and to have low intrinsic toxicity. These compounds will be "retro-designed" via cycle of synthetic medicinal chemistry followed by evaluation of compounds as menaquinone, and bacterial growth inhibitors. The compounds will also be counter-selected to reduce their effectiveness as cholesterol synthesis inhibitors. In addition, the mechanism of catalysis of MenA and alternative drug targets involved in menaquinone synthesis will be identified. The Specific Aims of this proposal are to: 1) Design, synthesize and test a new class of anti-tuberculosis agents derived from an oxidosqualene cyclase inhibitor. 2) test MenA, GrcC1, GrcC2, Rv0558 and Rv3853, genes hypothesized to participate in menaquinone synthesis in M. tuberculosis, for essentiality. 3) Define the mechanism of MenA catalysis, characterize the enzymatic properties of GrcC1, GrcC2, Rv0558 and Rv3853 and develop high-throughput screening compatible assays for those enzymes shown to be essential. Relevance: The results are expected to be of significance in terms of discovering new lead compounds that can be developed into new drugs to combat Gram-positive NIAID category A, B and C priority pathogens, as well as, emerging diseases caused by Gram-positive bacteria. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=7488671

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2203", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2206", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "USD", 
      "type": "MonetaryAmount", 
      "value": "320260"
    }, 
    "description": "Project Summary: Potent inhibitors of menaquinone synthesis (specifically MenA) in M. tuberculosis have been identified, which are also effective inhibitors of mycobacterial growth. Since utilization of menaquinone is a characteristic of Gram-positive organisms, these compounds are also active against organisms such as methicillin resistant Stapylococcus aureus and Staphylococcus epidermidis, and are expected to be effective against Bacillus anthracis and Listeria monocytogenes as well. The compounds identified as MenA inhibitors here, were first developed as cholesterol synthesis inhibitors and, as such, are known to be bioavailable in mammals and to have low intrinsic toxicity. These compounds will be \"retro-designed\" via cycle of synthetic medicinal chemistry followed by evaluation of compounds as menaquinone, and bacterial growth inhibitors. The compounds will also be counter-selected to reduce their effectiveness as cholesterol synthesis inhibitors. In addition, the mechanism of catalysis of MenA and alternative drug targets involved in menaquinone synthesis will be identified. The Specific Aims of this proposal are to: 1) Design, synthesize and test a new class of anti-tuberculosis agents derived from an oxidosqualene cyclase inhibitor. 2) test MenA, GrcC1, GrcC2, Rv0558 and Rv3853, genes hypothesized to participate in menaquinone synthesis in M. tuberculosis, for essentiality. 3) Define the mechanism of MenA catalysis, characterize the enzymatic properties of GrcC1, GrcC2, Rv0558 and Rv3853 and develop high-throughput screening compatible assays for those enzymes shown to be essential. Relevance: The results are expected to be of significance in terms of discovering new lead compounds that can be developed into new drugs to combat Gram-positive NIAID category A, B and C priority pathogens, as well as, emerging diseases caused by Gram-positive bacteria.", 
    "endDate": "2008-03-14T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.419681.3", 
      "type": "Organization"
    }, 
    "id": "sg:grant.2665876", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "2665876"
        ]
      }, 
      {
        "name": "nih_id", 
        "type": "PropertyValue", 
        "value": [
          "R56AI049151"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "Gram-positive NIAID category A", 
      "significance", 
      "Rv3853", 
      "menaquinone biosynthesis", 
      "effectiveness", 
      "compounds", 
      "MENA", 
      "menaquinone", 
      "genes", 
      "essentiality", 
      "addition", 
      "Gram-positive organisms", 
      "MenA inhibitors", 
      "M. tuberculosis", 
      "oxidosqualene cyclase inhibitors", 
      "terms", 
      "Bacillus anthracis", 
      "MenA catalysis", 
      "new lead compounds", 
      "drug targets", 
      "Listeria monocytogenes", 
      "mechanism", 
      "characteristics", 
      "GrcC1", 
      "Specific Aims", 
      "cholesterol synthesis inhibitor", 
      "priority pathogens", 
      "low intrinsic toxicity", 
      "disease", 
      "mycobacterial growth", 
      "GrcC2", 
      "test MenA", 
      "enzymatic properties", 
      "utilization", 
      "design", 
      "menaquinone synthesis", 
      "bacterial growth inhibitors", 
      "mammals", 
      "new class", 
      "results", 
      "synthetic medicinal chemistry", 
      "organisms", 
      "project summaries", 
      "Rv0558", 
      "enzyme", 
      "potent inhibitor", 
      "relevance", 
      "resistant Stapylococcus aureus", 
      "effective inhibitor", 
      "methicillin", 
      "evaluation", 
      "compatible assay", 
      "cycles", 
      "alternative drug targets", 
      "proposal", 
      "Gram-positive bacteria", 
      "catalysis", 
      "Staphylococcus epidermidis", 
      "new drugs", 
      "anti-tuberculosis agents"
    ], 
    "name": "Menaquinone biosynthesis: a drug target in Gram-positive bacteria", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.47894.36", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.47894.36", 
          "name": "COLORADO STATE UNIVERSITY-FORT COLLINS", 
          "type": "Organization"
        }, 
        "familyName": "CRICK", 
        "givenName": "DEAN C", 
        "id": "sg:person.01152425511.56", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.01152425511.56", 
        "roleName": "PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.2665876"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2019-03-07T12:06", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_18.xml.gz", 
    "startDate": "2001-02-01T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=7488671"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2665876'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2665876'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2665876'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2665876'


 

This table displays all metadata directly associated to this object as RDF triples.

110 TRIPLES      19 PREDICATES      84 URIs      74 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:grant.2665876 schema:about anzsrc-for:2203
2 anzsrc-for:2206
3 anzsrc-for:2211
4 schema:amount N89711dfb7c98418c8fcdb22819f8bf22
5 schema:description Project Summary: Potent inhibitors of menaquinone synthesis (specifically MenA) in M. tuberculosis have been identified, which are also effective inhibitors of mycobacterial growth. Since utilization of menaquinone is a characteristic of Gram-positive organisms, these compounds are also active against organisms such as methicillin resistant Stapylococcus aureus and Staphylococcus epidermidis, and are expected to be effective against Bacillus anthracis and Listeria monocytogenes as well. The compounds identified as MenA inhibitors here, were first developed as cholesterol synthesis inhibitors and, as such, are known to be bioavailable in mammals and to have low intrinsic toxicity. These compounds will be "retro-designed" via cycle of synthetic medicinal chemistry followed by evaluation of compounds as menaquinone, and bacterial growth inhibitors. The compounds will also be counter-selected to reduce their effectiveness as cholesterol synthesis inhibitors. In addition, the mechanism of catalysis of MenA and alternative drug targets involved in menaquinone synthesis will be identified. The Specific Aims of this proposal are to: 1) Design, synthesize and test a new class of anti-tuberculosis agents derived from an oxidosqualene cyclase inhibitor. 2) test MenA, GrcC1, GrcC2, Rv0558 and Rv3853, genes hypothesized to participate in menaquinone synthesis in M. tuberculosis, for essentiality. 3) Define the mechanism of MenA catalysis, characterize the enzymatic properties of GrcC1, GrcC2, Rv0558 and Rv3853 and develop high-throughput screening compatible assays for those enzymes shown to be essential. Relevance: The results are expected to be of significance in terms of discovering new lead compounds that can be developed into new drugs to combat Gram-positive NIAID category A, B and C priority pathogens, as well as, emerging diseases caused by Gram-positive bacteria.
6 schema:endDate 2008-03-14T00:00:00Z
7 schema:funder https://www.grid.ac/institutes/grid.419681.3
8 schema:identifier Na0a3e0d18c574085a8ccd7c22b0d2016
9 Nbbabc7089bd44f7eaecbbb478b35a8d3
10 schema:inLanguage en
11 schema:keywords Bacillus anthracis
12 Gram-positive NIAID category A
13 Gram-positive bacteria
14 Gram-positive organisms
15 GrcC1
16 GrcC2
17 Listeria monocytogenes
18 M. tuberculosis
19 MENA
20 MenA catalysis
21 MenA inhibitors
22 Rv0558
23 Rv3853
24 Specific Aims
25 Staphylococcus epidermidis
26 addition
27 alternative drug targets
28 anti-tuberculosis agents
29 bacterial growth inhibitors
30 catalysis
31 characteristics
32 cholesterol synthesis inhibitor
33 compatible assay
34 compounds
35 cycles
36 design
37 disease
38 drug targets
39 effective inhibitor
40 effectiveness
41 enzymatic properties
42 enzyme
43 essentiality
44 evaluation
45 genes
46 low intrinsic toxicity
47 mammals
48 mechanism
49 menaquinone
50 menaquinone biosynthesis
51 menaquinone synthesis
52 methicillin
53 mycobacterial growth
54 new class
55 new drugs
56 new lead compounds
57 organisms
58 oxidosqualene cyclase inhibitors
59 potent inhibitor
60 priority pathogens
61 project summaries
62 proposal
63 relevance
64 resistant Stapylococcus aureus
65 results
66 significance
67 synthetic medicinal chemistry
68 terms
69 test MenA
70 utilization
71 schema:name Menaquinone biosynthesis: a drug target in Gram-positive bacteria
72 schema:recipient Nd1384841fc9b46c3835a716583d0e3db
73 sg:person.01152425511.56
74 https://www.grid.ac/institutes/grid.47894.36
75 schema:sameAs https://app.dimensions.ai/details/grant/grant.2665876
76 schema:sdDatePublished 2019-03-07T12:06
77 schema:sdLicense https://scigraph.springernature.com/explorer/license/
78 schema:sdPublisher N2725066a782e4965aa2bbec8c36cffd6
79 schema:startDate 2001-02-01T00:00:00Z
80 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=7488671
81 sgo:license sg:explorer/license/
82 sgo:sdDataset grants
83 rdf:type schema:MonetaryGrant
84 N2725066a782e4965aa2bbec8c36cffd6 schema:name Springer Nature - SN SciGraph project
85 rdf:type schema:Organization
86 N89711dfb7c98418c8fcdb22819f8bf22 schema:currency USD
87 schema:value 320260
88 rdf:type schema:MonetaryAmount
89 Na0a3e0d18c574085a8ccd7c22b0d2016 schema:name dimensions_id
90 schema:value 2665876
91 rdf:type schema:PropertyValue
92 Nbbabc7089bd44f7eaecbbb478b35a8d3 schema:name nih_id
93 schema:value R56AI049151
94 rdf:type schema:PropertyValue
95 Nd1384841fc9b46c3835a716583d0e3db schema:member sg:person.01152425511.56
96 schema:roleName PI
97 rdf:type schema:Role
98 anzsrc-for:2203 schema:inDefinedTermSet anzsrc-for:
99 rdf:type schema:DefinedTerm
100 anzsrc-for:2206 schema:inDefinedTermSet anzsrc-for:
101 rdf:type schema:DefinedTerm
102 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
103 rdf:type schema:DefinedTerm
104 sg:person.01152425511.56 schema:affiliation https://www.grid.ac/institutes/grid.47894.36
105 schema:familyName CRICK
106 schema:givenName DEAN C
107 rdf:type schema:Person
108 https://www.grid.ac/institutes/grid.419681.3 schema:Organization
109 https://www.grid.ac/institutes/grid.47894.36 schema:name COLORADO STATE UNIVERSITY-FORT COLLINS
110 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...